{"transactions":[{"id":1086308,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2025-07-16T16:55:04.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":48100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This Form 4 is being filed late as the result of an inadvertent administrative oversight."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":48100,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":48100},"source":{"system":"sec-edgar","filing":"0001641172-25-019858","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000164117225019858/ownership.xml","form_type":"4"}},{"id":1087181,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2025-07-15T20:22:52.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":60100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":60100,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":60100},"source":{"system":"sec-edgar","filing":"0001641172-25-019729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000164117225019729/ownership.xml","form_type":"4"}},{"id":1087180,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77494,"kind":"person","name":"Guzman Pablo A.","position":1,"cik":"0001963541","reported_name":"Guzman Pablo A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options","published_at":"2025-07-15T20:22:50.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":48900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":48900,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":48900},"source":{"system":"sec-edgar","filing":"0001641172-25-019726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000164117225019726/ownership.xml","form_type":"4"}},{"id":1087179,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77493,"kind":"person","name":"Park Min-Chul","position":1,"cik":"0001956022","reported_name":"Park Min-Chul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-15T20:22:49.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":11066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":11066,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":11066},"source":{"system":"sec-edgar","filing":"0001641172-25-019727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000164117225019727/ownership.xml","form_type":"4"}},{"id":1087343,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":63293,"kind":"person","name":"Freitag Gregory Gene","position":1,"cik":"0001492710","reported_name":"Freitag Gregory Gene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-15T16:22:57.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":11066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":11066,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":11066},"source":{"system":"sec-edgar","filing":"0001641172-25-019724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492710/000164117225019724/ownership.xml","form_type":"4"}},{"id":1087284,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2025-07-15T16:22:55.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":136900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":136900,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":136900},"source":{"system":"sec-edgar","filing":"0001641172-25-019725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000164117225019725/ownership.xml","form_type":"4"}},{"id":1087233,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77498,"kind":"person","name":"Finizio Robert G","position":1,"cik":"0001532235","reported_name":"Finizio Robert G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-15T16:22:54.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":11066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":11066,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":11066},"source":{"system":"sec-edgar","filing":"0001641172-25-019723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532235/000164117225019723/ownership.xml","form_type":"4"}},{"id":1087229,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-15T16:22:47.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":11066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":11066,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":11066},"source":{"system":"sec-edgar","filing":"0001641172-25-019728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000164117225019728/ownership.xml","form_type":"4"}},{"id":1451615,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-19T01:35:14.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":572,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":572},"source":{"system":"sec-edgar","filing":"0001493152-24-028400","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224028400/ownership.xml","form_type":"4"}},{"id":1451614,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2024-07-19T01:35:12.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":715,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":715},"source":{"system":"sec-edgar","filing":"0001493152-24-028405","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224028405/ownership.xml","form_type":"4"}},{"id":1451613,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77493,"kind":"person","name":"Park Min-Chul","position":1,"cik":"0001956022","reported_name":"Park Min-Chul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-19T01:35:09.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":132,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001493152-24-028401","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224028401/ownership.xml","form_type":"4"}},{"id":1451708,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2024-07-18T21:35:11.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":1627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":1627,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":1627},"source":{"system":"sec-edgar","filing":"0001493152-24-028404","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315224028404/ownership.xml","form_type":"4"}},{"id":1451772,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":63293,"kind":"person","name":"Freitag Gregory Gene","position":1,"cik":"0001492710","reported_name":"Freitag Gregory Gene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-18T21:35:08.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":132,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001493152-24-028399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492710/000149315224028399/ownership.xml","form_type":"4"}},{"id":1451678,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-18T21:35:06.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":132,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001493152-24-028403","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000149315224028403/ownership.xml","form_type":"4"}},{"id":1451684,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77498,"kind":"person","name":"Finizio Robert G","position":1,"cik":"0001532235","reported_name":"Finizio Robert G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-18T21:35:05.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":132,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001493152-24-028402","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532235/000149315224028402/ownership.xml","form_type":"4"}},{"id":2044586,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77494,"kind":"person","name":"Guzman Pablo A.","position":1,"cik":"0001963541","reported_name":"Guzman Pablo A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (right to buy)","published_at":"2023-01-27T01:25:12.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 3 equal annual installments commencing on January 26, 2024."}],"balance_after":100000,"derivative":{"exercise_price":2.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-23-002653","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223002653/ownership.xml","form_type":"4"}},{"id":2079330,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-20T21:00:18.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":3000,"price":2.8815,"value":8644.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.97 per share,\ninclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission,\nupon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":44585,"source":{"system":"sec-edgar","filing":"0001493152-22-035985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035985/ownership.xml","form_type":"4"}},{"id":2084061,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":110893,"kind":"organization","name":"INCON Co., Ltd.","position":1,"cik":"0001958829","reported_name":"INCON Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-12-16T21:41:09.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":450702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The warrant is immediately exercisable in full."}],"balance_after":450702,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":450702},"source":{"system":"sec-edgar","filing":"0001493152-22-035808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1958829/000149315222035808/ownership.xml","form_type":"4"}},{"id":2084060,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":110893,"kind":"organization","name":"INCON Co., Ltd.","position":1,"cik":"0001958829","reported_name":"INCON Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-16T21:41:09.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":1497199,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1497199,"source":{"system":"sec-edgar","filing":"0001493152-22-035808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1958829/000149315222035808/ownership.xml","form_type":"4"}},{"id":2086041,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":11763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant is immediately exercisable in full."}],"balance_after":11763,"derivative":{"exercise_price":11.58,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":11763},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086040,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrant is immediately exercisable in full."}],"balance_after":18058,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":18058},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086039,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":21840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":21840,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":21840},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086038,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":21840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":21840,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":21840},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086037,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":39708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":39708,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":39708},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086036,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017."}],"balance_after":9927,"derivative":{"exercise_price":5.09,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086035,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on October 21, 2016."}],"balance_after":9927,"derivative":{"exercise_price":5.09,"expiration_date":"2025-10-21","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086034,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77495,"kind":"person","name":"Wolfe Peter","position":1,"cik":"0001954398","reported_name":"Wolfe Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-15T00:37:39.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":41585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."}],"balance_after":41585,"source":{"system":"sec-edgar","filing":"0001493152-22-035487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035487/ownership.xml","form_type":"4"}},{"id":2086033,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77493,"kind":"person","name":"Park Min-Chul","position":1,"cik":"0001956022","reported_name":"Park Min-Chul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:34:27.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":9927,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035485/ownership.xml","form_type":"4"}},{"id":2086032,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77493,"kind":"person","name":"Park Min-Chul","position":1,"cik":"0001956022","reported_name":"Park Min-Chul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:34:27.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the option is immediately exercisable. The option vested on July 1, 2021."}],"balance_after":29781,"derivative":{"exercise_price":16.36,"expiration_date":"2031-07-01","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035485/ownership.xml","form_type":"4"}},{"id":2086028,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:27:56.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":21840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":21840,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":21840},"source":{"system":"sec-edgar","filing":"0001493152-22-035481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035481/ownership.xml","form_type":"4"}},{"id":2086027,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:27:56.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":21840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":21840,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":21840},"source":{"system":"sec-edgar","filing":"0001493152-22-035481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035481/ownership.xml","form_type":"4"}},{"id":2086026,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:27:56.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":29781,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035481/ownership.xml","form_type":"4"}},{"id":2086025,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:27:56.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":19854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017."}],"balance_after":19854,"derivative":{"exercise_price":5.03,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":19854},"source":{"system":"sec-edgar","filing":"0001493152-22-035481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035481/ownership.xml","form_type":"4"}},{"id":2086024,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77458,"kind":"person","name":"Cashmere Karen A.","position":1,"cik":"0001954546","reported_name":"Cashmere Karen A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-15T00:27:56.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on September 10, 2014."}],"balance_after":9927,"derivative":{"exercise_price":5.03,"expiration_date":"2024-09-10","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222035481/ownership.xml","form_type":"4"}},{"id":2086264,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":121622,"kind":"organization","name":"Larkspur Health LLC","position":2,"cik":"0001915818","reported_name":"Larkspur Health LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-12-15T00:21:31.000Z","date":"2022-12-12","kind":"other","acquired":true,"shares":177204,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrant is immediately exercisable in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held of record by Larkspur Health LLC (the \"Sponsor\"). Daniel J. O'Connor is the sole manager of Larkspur Health LLC and in such capacity has voting and investment discretion with respect to the common stock held of record by Larkspur Health LLC. By virtue of this relationship, Mr. O'Connor may be deemed to have beneficial ownership of the securities held of record by the Sponsor. Mr. O'Connor disclaims any such beneficial ownership except to the extent of his pecuniary interest."}],"balance_after":177204,"derivative":{"exercise_price":11.5,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":177204},"source":{"system":"sec-edgar","filing":"0001493152-22-035477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000149315222035477/ownership.xml","form_type":"4"}},{"id":2086263,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":121622,"kind":"organization","name":"Larkspur Health LLC","position":2,"cik":"0001915818","reported_name":"Larkspur Health LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-12-15T00:21:31.000Z","date":"2022-12-12","kind":"other","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. O'Connor paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrant is immediately exercisable in full."}],"balance_after":1750,"derivative":{"exercise_price":11.5,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001493152-22-035477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000149315222035477/ownership.xml","form_type":"4"}},{"id":2086262,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":121622,"kind":"organization","name":"Larkspur Health LLC","position":2,"cik":"0001915818","reported_name":"Larkspur Health LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-12-15T00:21:31.000Z","date":"2022-12-12","kind":"other","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. O'Connor paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":1750,"derivative":{"exercise_price":10,"exercise_date":"2022-12-12","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001493152-22-035477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000149315222035477/ownership.xml","form_type":"4"}},{"id":2086261,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":121622,"kind":"organization","name":"Larkspur Health LLC","position":2,"cik":"0001915818","reported_name":"Larkspur Health LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-15T00:21:31.000Z","date":"2022-12-12","kind":"other","acquired":true,"shares":1377598,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held of record by Larkspur Health LLC (the \"Sponsor\"). Daniel J. O'Connor is the sole manager of Larkspur Health LLC and in such capacity has voting and investment discretion with respect to the common stock held of record by Larkspur Health LLC. By virtue of this relationship, Mr. O'Connor may be deemed to have beneficial ownership of the securities held of record by the Sponsor. Mr. O'Connor disclaims any such beneficial ownership except to the extent of his pecuniary interest."}],"balance_after":1377598,"source":{"system":"sec-edgar","filing":"0001493152-22-035477","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000149315222035477/ownership.xml","form_type":"4"}},{"id":2086176,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77498,"kind":"person","name":"Finizio Robert G","position":1,"cik":"0001532235","reported_name":"Finizio Robert G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:40:42.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":9927,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001493152-22-035489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532235/000149315222035489/ownership.xml","form_type":"4"}},{"id":2086175,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77498,"kind":"person","name":"Finizio Robert G","position":1,"cik":"0001532235","reported_name":"Finizio Robert G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:40:42.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":19854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":19854,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":19854},"source":{"system":"sec-edgar","filing":"0001493152-22-035489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532235/000149315222035489/ownership.xml","form_type":"4"}},{"id":2086174,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":77498,"kind":"person","name":"Finizio Robert G","position":1,"cik":"0001532235","reported_name":"Finizio Robert G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:40:42.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":29781,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532235/000149315222035489/ownership.xml","form_type":"4"}},{"id":2086445,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant is immediately exercisable in full."}],"balance_after":18094,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":18094},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086444,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":29781,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086443,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":29781,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086442,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":39708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":39708,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":39708},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086441,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":59563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017."}],"balance_after":59563,"derivative":{"exercise_price":5.03,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":59563},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086440,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":39709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016."}],"balance_after":39709,"derivative":{"exercise_price":5.03,"expiration_date":"2025-06-09","underlying":"Common Stock","underlying_shares":39709},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086439,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":19854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015."}],"balance_after":19854,"derivative":{"exercise_price":5.03,"expiration_date":"2024-04-11","underlying":"Common Stock","underlying_shares":19854},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086438,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18094,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."}],"balance_after":18094,"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086305,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."}],"balance_after":1750,"derivative":{"exercise_price":11.5,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086304,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":17903,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Asclepius Life Sciences Fund, L.P (\"ALS Fund\"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":17903,"derivative":{"exercise_price":11.58,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":17903},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086303,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":3022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."}],"balance_after":3022,"derivative":{"exercise_price":11.58,"expiration_date":"2023-10-31","underlying":"Common Stock","underlying_shares":3022},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086302,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":70881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrant is immediately exercisable in full."}],"balance_after":70881,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":70881},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086301,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":79417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":79417,"derivative":{"exercise_price":16.36,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":79147},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086300,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":126138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":126138,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":126138},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086299,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":264838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":264838,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":264838},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086298,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":168761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the option is immediately exercisable. The option vested on October 28, 2016."}],"balance_after":168761,"derivative":{"exercise_price":5.03,"expiration_date":"2026-10-28","underlying":"Common Stock","underlying_shares":168761},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086297,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":138980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015."}],"balance_after":138980,"derivative":{"exercise_price":5.03,"expiration_date":"2024-04-11","underlying":"Common Stock","underlying_shares":138980},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086296,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":1750,"derivative":{"exercise_price":10,"exercise_date":"2022-12-12","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086295,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":43847,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held of record by MedicaRx Inc. (\"MRx\"). Reporting Person serves as the managing director of MRx. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":43847,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086294,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":49636,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held of record by Asclepius Master Fund, LTD. (\"AM Fund\"). Reporting Person serves as the managing director of AM Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":49636,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086293,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":85442,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Asclepius Life Sciences Fund, L.P (\"ALS Fund\"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":85442,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2086292,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41889,"kind":"person","name":"Glover Stephen C.","position":1,"cik":"0001304406","reported_name":"Glover Stephen C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:24:50.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":448909,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."}],"balance_after":448909,"source":{"system":"sec-edgar","filing":"0001493152-22-035479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304406/000149315222035479/ownership.xml","form_type":"4"}},{"id":2339118,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121622,"kind":"organization","name":"Larkspur Health LLC","position":1,"cik":"0001915818","reported_name":"Larkspur Health LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2022-03-10T22:32:48.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":3427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the reporting person for no consideration."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the reporting person for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"}],"balance_after":1141326,"derivative":{"underlying":"Class A Common Stock","underlying_shares":3427},"source":{"system":"sec-edgar","filing":"0001213900-22-011646","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022011646/ownership.xml","form_type":"4"}},{"id":2339117,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121622,"kind":"organization","name":"Larkspur Health LLC","position":1,"cik":"0001915818","reported_name":"Larkspur Health LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-03-10T22:32:48.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":236273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Reporting Person in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased."}],"balance_after":236273,"source":{"system":"sec-edgar","filing":"0001213900-22-011646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022011646/ownership.xml","form_type":"4"}},{"id":2339464,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B common stock","published_at":"2022-03-10T22:31:16.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":609,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the Sponsor for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares represent those owned by Mr. O'Connor, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC."}],"balance_after":201848,"derivative":{"underlying":"Class A common stock","underlying_shares":609},"source":{"system":"sec-edgar","filing":"0001213900-22-011644","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000121390022011644/ownership.xml","form_type":"4"}},{"id":2339463,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B common stock","published_at":"2022-03-10T22:31:16.000Z","date":"2022-01-06","kind":"other","acquired":false,"shares":23404,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"shares","element":"transactionShares","label":"F4","text":"As contemplated in connection with the initial public offering of the Issuer, 22,343 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares represent those owned by Mr. O'Connor, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC."}],"balance_after":201239,"derivative":{"underlying":"Class A common stock","underlying_shares":23404},"source":{"system":"sec-edgar","filing":"0001213900-22-011644","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000121390022011644/ownership.xml","form_type":"4"}},{"id":2339462,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41698,"kind":"person","name":"O'Connor Daniel J.","position":1,"cik":"0001376847","reported_name":"O'Connor Daniel J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2022-03-10T22:31:16.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":42005,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the \"Sponsor\") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the \"Sponsor\") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares represent those owned by Mr. O'Connor, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC."}],"balance_after":42005,"source":{"system":"sec-edgar","filing":"0001213900-22-011644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376847/000121390022011644/ownership.xml","form_type":"4"}},{"id":2339174,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":95157,"kind":"person","name":"Mehra Raj","position":1,"cik":"0001757892","reported_name":"Mehra Raj","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B common stock","published_at":"2022-03-10T17:32:02.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F2","text":"As contemplated in connection with the initial public offering of the Issuer, 953 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"}],"balance_after":8631,"derivative":{"underlying":"Class A common stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0001213900-22-011645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757892/000121390022011645/ownership.xml","form_type":"4"}},{"id":2340090,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B common stock","published_at":"2022-03-10T17:30:58.000Z","date":"2022-01-06","kind":"other","acquired":false,"shares":953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F2","text":"As contemplated in connection with the initial public offering of the Issuer, 953 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"}],"balance_after":8631,"derivative":{"underlying":"Class A common stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0001213900-22-011643","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000121390022011643/ownership.xml","form_type":"4"}},{"id":2340095,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":129267,"kind":"person","name":"Skalicky Gregory","position":1,"cik":"0001878571","reported_name":"Skalicky Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B common stock","published_at":"2022-03-10T17:30:35.000Z","date":"2022-01-06","kind":"other","acquired":false,"shares":953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F2","text":"As contemplated in connection with the initial public offering of the Issuer, 953 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"}],"balance_after":8631,"derivative":{"underlying":"Class A common stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0001213900-22-011642","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878571/000121390022011642/ownership.xml","form_type":"4"}},{"id":2339325,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":79751,"kind":"person","name":"Briones David S.","position":1,"cik":"0001599831","reported_name":"Briones David S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class B common stock","published_at":"2022-03-10T17:30:21.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":91,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the partial exercise of the underwriters' over-allotment option, A.G.P./Alliance Global Partners transferred 3,427 shares to the Sponsor for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC."}],"balance_after":56123,"derivative":{"underlying":"Class A common stock","underlying_shares":156},"source":{"system":"sec-edgar","filing":"0001213900-22-011641","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1599831/000121390022011641/ownership.xml","form_type":"4"}},{"id":2339324,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":79751,"kind":"person","name":"Briones David S.","position":1,"cik":"0001599831","reported_name":"Briones David S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class B common stock","published_at":"2022-03-10T17:30:21.000Z","date":"2022-01-06","kind":"other","acquired":false,"shares":1533,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"shares","element":"transactionShares","label":"F4","text":"As contemplated in connection with the initial public offering of the Issuer, 22,343 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC."}],"balance_after":55967,"derivative":{"underlying":"Class A common stock","underlying_shares":1533},"source":{"system":"sec-edgar","filing":"0001213900-22-011641","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599831/000121390022011641/ownership.xml","form_type":"4"}},{"id":2339323,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":79751,"kind":"person","name":"Briones David S.","position":1,"cik":"0001599831","reported_name":"Briones David S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2022-03-10T17:30:21.000Z","date":"2022-01-06","kind":"other","acquired":true,"shares":10752,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the \"Sponsor\") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares are underlying units (each unit consisting of one share of Class A common stock and three-fourths of one warrant, each whole warrant exercisable to purchase one share of Class A common stock) acquired in a private placement by the Larkspur Health LLC (the \"Sponsor\") in connection with the issuer's initial public offering and subsequent partial exercise of the underwriters' over-allotment option. The above refers to the shares of Class A common stock included in the units purchased."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares represent those owned by Mr. Briones, a member of Larkspur Health LLC based on his pro rata share of ownership of Larkspur Health LLC."}],"balance_after":10752,"source":{"system":"sec-edgar","filing":"0001213900-22-011641","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599831/000121390022011641/ownership.xml","form_type":"4"}},{"id":2346126,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":129409,"kind":"organization","name":"A.G.P. / ALLIANCE GLOBAL PARTNERS CORP.","position":1,"cik":"0000318492","reported_name":"A.G.P. / ALLIANCE GLOBAL PARTNERS CORP.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2022-03-08T13:51:21.000Z","date":"2022-03-08","kind":"other","acquired":false,"shares":3427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares to certain investors for no consideration as contemplated in connection with Issuer's initial public offering because underwriters' over-allotment option was not fully exercised."}],"balance_after":446843,"source":{"system":"sec-edgar","filing":"0001209191-22-016941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318492/000120919122016941/doc4.xml","form_type":"4"}},{"id":2410867,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":129409,"kind":"organization","name":"A.G.P. / ALLIANCE GLOBAL PARTNERS CORP.","position":1,"cik":"0000318492","reported_name":"A.G.P. / ALLIANCE GLOBAL PARTNERS CORP.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2022-02-07T19:36:29.000Z","date":"2022-02-03","kind":"other","acquired":false,"shares":49730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Cancellation of 49,730 shares (\"Shares\") of Issuer's Class B common stock as contemplated in connection with Issuer's initial public offering. Such Shares were forfeited and cancelled for no consideration because underwriters' over-allotment option was not fully exercised."}],"balance_after":450270,"source":{"system":"sec-edgar","filing":"0001209191-22-007614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318492/000120919122007614/doc4.xml","form_type":"4"}}]}